<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-94D7B8ET/06d4c4c6-241d-4d4e-9a97-8e5b063df895/PDF"><dcterms:extent>707 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-94D7B8ET/ca168b40-dc68-4840-8452-4fa66afe86ef/TEXT"><dcterms:extent>34 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-94D7B8ET"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2022</dcterms:issued><dc:creator>Bogataj, Marija</dc:creator><dc:creator>Rede, Katarina</dc:creator><dc:format xml:lang="sl">številka:5</dc:format><dc:format xml:lang="sl">letnik:73</dc:format><dc:format xml:lang="sl">str. 395-402</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID_HOST:132620035</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-94D7B8ET</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">Dostavni sistemi</dc:subject><dc:subject xml:lang="sl">Encimi</dc:subject><dc:subject xml:lang="sl">Lipidi</dc:subject><dc:subject xml:lang="sl">lipidni dostavni sistemi</dc:subject><dc:subject xml:lang="sl">pankreasna lipaza</dc:subject><dc:subject xml:lang="sl">prebava</dc:subject><dc:subject xml:lang="sl">Zdravilne učinkovine</dc:subject><dc:subject xml:lang="sl">želodčna lipaza</dc:subject><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Prebavne lipaze in njihov pomen pri aplikaciji zdravil| Digestive lipases and their significance in drug delivery|</dc:title><dc:description xml:lang="sl">Digestive enzymes play an important role in food breakdown and they are also frequently involved in oral drug delivery. One of digestive enzyme groups is lipases, which catalyze the hydrolysis of lipids, resulting in the formation of digestion products that can be absorbed. The most important digestive lipases in humans are gastric and pancreatic lipases. Gastric lipase is an acid-stable enzyme, which is secreted from gastric mucosa. It initiates lipid digestion. Pancreatic lipase, which contributes to lipolysis to the greatest extent, is secreted from the pancreas into the duodenum and continues lipid digestion. The process of lipid digestion can also influence the bioavailability of a drug incorporated into lipid-based drug delivery systems, as components of these systems can be digested by lipases, and it can also affect oral lipid prodrugs. Therefore, knowledge about lipase activity is an important factor in the development of these drug delivery systems and their biopharmaceutical evaluation</dc:description><dc:description xml:lang="sl">Prebavni encimi imajo pomembno vlogo pri razgradnji hrane in marsikdaj tudi pri peroralni dostavi zdravilnih učinkovin. Ena izmed skupin prebavnih encimov so lipaze, katerih naloga je kataliza hidrolize lipidov, pri čemer nastanejo razgradni produkti, ki se lahko absorbirajo. Najpomembnejši prebavni lipazi pri človeku sta želodčna in pankreasna lipaza. Želodčna lipaza je acidostabilen encim, ki se izloča iz želodčne sluznice in začne z razgradnjo lipidov. Pankreasna lipaza, ki k lipolizi prispeva v največjem obsegu, se izloča iz trebušne slinavke v dvanajstnik in nadaljuje z razgradnjo lipidov. Proces razgradnje lipidov lahko vpliva na biološko uporabnost zdravilnih učinkovin, ki so vgrajene v lipidne dostavne sisteme, saj se lahko s pomočjo lipaz razgradijo komponente teh sistemov, in tudi na peroralna lipidna predzdravila. Poznavanje delovanja lipaz je zato pomemben dejavnik pri razvoju tovrstnih dostavnih sistemov in njihovem biofarmacevtskem vrednotenju</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-94D7B8ET"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-94D7B8ET" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-94D7B8ET/06d4c4c6-241d-4d4e-9a97-8e5b063df895/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-94D7B8ET/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-94D7B8ET" /></ore:Aggregation></rdf:RDF>